Bio-Thera Solutions

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

2 drugs in development

Approved1

Phase 31

Phase 21

By Therapeutic Area

top 2

Neurology

267%

Ophthalmology

133%

R&D Momentum

40/100

Pipeline Velocity

6/100

Trial Completion Rate

78/100

Pipeline Concentration

56/100

Pipeline Freshness

61/100

Strategic Signals

↗Active in Ophthalmology but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Jul 11, 2026

Completed

Phase Ib/IIa Study to Evaluate the Safety and Efficacy of Intravitreal Administration of Two Doses of BAT5906 Injection With Multiple Dosing Regimens in Patients With Diabetic Macular Edema

Earlier

Mar 11, 2026TrialHARMONY: Fremanezumab Preventive in Episodic Migraine

Oct 14, 2025TrialA Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants

Jan 31, 2025TrialA Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer

Jul 19, 2024TrialA Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC

May 8, 2024TrialA Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors

Apr 12, 2024TrialA Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors

Apr 9, 2024TrialBAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer

4 more events

Mar 6, 2024TrialAssessment of Safety, Tolerability and Pharmacokinetics With BAT4706 and BAT1308 in Advanced Solid Tumors Patients

Dec 13, 2023TrialBAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer

Dec 6, 2023FDAAvastin — AVZIVI TNJN

Nov 9, 2023TrialEvaluate the Safety, Tolerability of BAT6026

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

QLETLIApproved

Regulatory

Regulatory Timeline

20042 events

FDAFeb 26

Avastin — Avastin

Application 125085 (BLA)

FDAFeb 26

Avastin — AVASTIN

Application BLA125085 (BLA)

20231 event

FDADec 6

Avastin — AVZIVI TNJN

Application BLA761198 (BLA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)